Silence Therapeutics plc — Director's Dealing 2025

Apr 1, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Silence Therapeutics plc (SLN)
CIK: 0001479615
Period of Report: 2025-03-31

Reporting Person: Griffiths Richard Ian (10% Owner)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-03-31	American Depositary Shares	$2.83	P	100000	Acquired		Ordinary Shares (300000)	Indirect

Footnotes

F1: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date.

F2: The securities transactions listed were made by Cream Capital Limited ("Cream"). Mr Griffiths is a director and the controlling shareholder of Cream. Mr Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.